In a PhIII showdown with Spark, uniQure switches out its lead gene therapy for hemophilia B – Endpoints News
Endpoints News |
In a PhIII showdown with Spark, uniQure switches out its lead gene therapy for hemophilia B
Endpoints News Late last year, the struggling gene therapy biotech uniQure $QURE did some painful cost cutting, dropping programs, axing staff and tailoring the pipeline to concentrate on a hemophilia B program for AMT-060, which they said could be hustled through a … |
